Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Yifan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2821-1953; OpenAlex author ID A5100398594. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 6 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers

Papers 20

  1. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  2. Integrative analysis of pancreatic microbiota and metabolome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-27942-6↗
  3. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  4. Microbiome and metabolome analysis in smoking and non-smoking pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s12866-024-03688-5↗
  5. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  6. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. First author DOI 10.1038/s41416-023-02214-0↗
  7. Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review. Co-author DOI 10.1080/17474124.2022.2020643↗
  8. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. Co-author DOI 10.1136/jmedgenet-2021-108054↗
  9. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  10. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  11. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2022.860767↗
  12. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  13. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  14. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  15. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. Co-author DOI 10.6004/jnccn.2021.7049↗
  16. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-2803↗
  17. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3724↗
  18. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  19. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Co-author DOI 10.3390/genes11091098↗
  20. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Zogopoulos · 17 shared papers, 2019–2025 · strength 1.98
  2. Steve Gallinger · 13 shared papers, 2019–2025 · strength 1.39
  3. Grainne Mary O'Kane · 12 shared papers, 2020–2025 · strength 1.32
  4. Robert C. Grant · 11 shared papers, 2020–2025 · strength 1.25
  5. Jennifer Jane Knox · 11 shared papers, 2020–2025 · strength 1.21
  6. Sandra Elisabeth Fischer · 11 shared papers, 2020–2025 · strength 1.15
  7. Faiyaz Notta · 9 shared papers, 2020–2025 · strength 1.02
  8. Barbara T. Grünwald · 7 shared papers, 2020–2025 · strength 0.83
  9. Spring Holter · 7 shared papers, 2019–2025 · strength 0.77
  10. Ayelet Borgida · 7 shared papers, 2019–2025 · strength 0.73
  11. Zu‐Hua Gao · 5 shared papers, 2020–2022 · strength 0.57
  12. James Biagi · 4 shared papers, 2020–2023 · strength 0.43
  13. Yiqing Zhu · 2 shared papers, 2024–2025 · strength 0.41
  14. Xiao Liang · 2 shared papers, 2024–2025 · strength 0.41
  15. Ravi Ramjeesingh · 3 shared papers, 2022–2025 · strength 0.40
  16. Mustapha Ali Tehfe · 3 shared papers, 2022–2025 · strength 0.40
  17. Rama Khokha · 4 shared papers, 2020–2023 · strength 0.39
  18. Bryn Golesworthy · 3 shared papers, 2022 · strength 0.36
  19. Joan Miguel Romero · 3 shared papers, 2020–2025 · strength 0.34
  20. Michelle Chan‐Seng‐Yue · 2 shared papers, 2025 · strength 0.33
  21. Erica S. Tsang · 2 shared papers, 2025 · strength 0.33
  22. Talia Golan · 3 shared papers, 2020–2024 · strength 0.30
  23. Sheron Perera · 2 shared papers, 2022–2025 · strength 0.27
  24. Xiaowei Liu · 1 shared paper, 2022 · strength 0.26
  25. Raymond Jang · 2 shared papers, 2021–2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.